Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: 2nd Edition
share announcement

Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: 2nd Edition

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 3291

Special Issue Editors

Dr. Jose Carlos Armario Hita

E-Mail Website1 Website2
Guest Editor
Department of Dermatology, Hospital Universitario de Puerto Real, 11510 Puerto Real, Spain
Interests: atopic dermatitis; psoriasis; biological treatment; contact dermatitis; urticaria
Dr. Jose Juan Pereyra Rodriguez

E-Mail Website
Guest Editor
Department of Dermatology, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain
Interests: atopic dermatitis; psoriasis; biological treatment; contact dermatitis; urticaria
Special Issues, Collections and Topics in MDPI journals
Dr. Ricardo Ruiz-Villaverde

E-Mail Website
Guest Editor
Dermatology Department, Hospital Universitario San Cecilio, Instituto Biosanitario de Granada, Ibs, 18016 Granada, Spain
Interests: psoriasis; atopic dermatitis; biological treatments
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following the success of the first volume of our Special Issue “Mechanism, Diagnostic and Therapeutic Novelties in Dermatology”, we now invite high-quality submissions for volume II in the Medical Research Section. The first volume is available at https://www.mdpi.com/journal/life/special_issues/610FW69Y66.

Dermatology is one of the oldest specialties and yet one of the most innovative and constantly evolving ones, too. It is a fairly self-sufficient specialty, as the accessibility of the skin, mucous membranes, appendages, etc., allows for a diagnosis without resorting to complementary means on many occasions. However, there is currently a real revolution in the understanding of the pathophysiological mechanisms of different inflammatory and tumoral skin diseases, in the complementary techniques that we use to develop diagnoses (ultrasonography, dermoscopy, confocal microscopy, etc.), and in the availability of alternative approaches to treatment which use biological drugs and synthetic molecules of high economic impact.

For all of these reasons, we believe that this Special Issue of Life is incredibly topical, and we are looking forward to gathering all of those novel aspects that incur in the pathophysiology, diagnosis and treatment of skin diseases.

Dr. Jose Carlos Armario Hita
Dr. Jose Juan Pereyra Rodriguez
Dr. Ricardo Ruiz-Villaverde
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • physiopathology
  • skin sonography
  • dermoscopy
  • innovation
  • confocal microscopy
  • biological treatment
  • psoriasis
  • atopic dermatitis
  • immune-mediated diseases
  • urticaria
  • laser CO2

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1011 KiB  
Article
Deficit of Omega-3 Fatty Acids in Acne Patients—A Cross-Sectional Pilot Study in a German Cohort
by Anne Guertler, Tobias Fiedler, Diana Lill, Anne-Charlotte Kuna, Arina Volsky, Jens Wallmichrath, Till Kämmerer, Lars E. French and Markus Reinholz
Life 2024, 14(4), 519; https://doi.org/10.3390/life14040519 - 17 Apr 2024
Viewed by 407
Abstract
Omega-3 fatty acids (ω-3 FAs) exert anti-inflammatory effects, including the downregulation of pro-inflammatory cytokines, eicosanoids, and insulin-like growth factor-1. Therefore, they may improve acne severity as an adjunct treatment. However, there is a paucity of data regarding patients’ existing deficits. The aim of [...] Read more.
Omega-3 fatty acids (ω-3 FAs) exert anti-inflammatory effects, including the downregulation of pro-inflammatory cytokines, eicosanoids, and insulin-like growth factor-1. Therefore, they may improve acne severity as an adjunct treatment. However, there is a paucity of data regarding patients’ existing deficits. The aim of this study was to determine ω-3 FA levels in acne patients in correlation with self-reported dietary preferences and clinical severity. A single-center, cross-sectional study of 100 acne patients was conducted. Patients’ blood parameters, including ω-3 FAs levels, were assessed using the HS-omega-3 Index® in erythrocytes (Omegametrix® GmbH, Martinsried, Germany). Dietary preferences were assessed using a standardized food frequency questionnaire. Clinical dermatologic evaluation was performed using the Investigator Global Assessment (IGA) of acne. The values of the HS-omega-3 Index® were outside the recommended range of 8–11% in 96 patients (mean 5.15%), independent of the clinical severity or affected anatomic sites. A severe deficit (HS-omega-3 Index® < 4%) was seen more commonly in men than in women (p = 0.021). The regular consumption of legumes was significantly associated with higher ω-3 FA levels (p = 0.003), as was oral ω-3 FA supplementation (p = 0.006) and the lack of sunflower oil intake (p = 0.008). This pilot study demonstrated a deficit of ω-3 FAs in a German acne cohort. Higher ω-3 FAs levels were observed in patients with regular legume intake and oral ω-3 FAs supplementation. Further prospective studies are needed to investigate whether the clinical severity of acne improves in patients with normal HS-omega-3 Index®. Full article
(This article belongs to the Special Issue Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: 2nd Edition)
►▼ Show Figures

Figure 1

10 pages, 1487 KiB  
Communication
Primary Cutaneous CD4 Small/Medium T-Cell Lymphoproliferative Disorder Following COVID-19 Vaccination—What Do We Know about Lymphoproliferative Disorders and Cutaneous Lymphomas after COVID-19 Vaccination? A Report of an Atypical Case and a Review of the Literature
by Francisco Javier De la Torre-Gomar, Jose María Llamas-Molina, Maria Dolores Pegalajar-García, Carmen Pérez-Valencia, Alejandro Carrero-Castaño and Ricardo Ruiz-Villaverde
Life 2024, 14(3), 386; https://doi.org/10.3390/life14030386 - 14 Mar 2024
Viewed by 1023
Abstract
The association between Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD) and COVID-19 immunization has been sparsely documented in the medical literature. Reviewing the literature, albeit infrequently, we can find cases of the recurrence and new onset of lymphoproliferative processes and cutaneous lymphomas [...] Read more.
The association between Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD) and COVID-19 immunization has been sparsely documented in the medical literature. Reviewing the literature, albeit infrequently, we can find cases of the recurrence and new onset of lymphoproliferative processes and cutaneous lymphomas following the COVID-19 vaccine. Many of the entities we encounter are classified as cutaneous lymphoproliferative disorders. The prevailing hypothesis suggests that the predominant cutaneous reactions to SARS-CoV-2 vaccines may stem from T-cell-mediated immune activation responses to vaccine components, notably messenger RNA (mRNA). Specifically, it is posited that the presence of cutaneous lymphoid infiltrates may be linked to immune system stimulation, supported by the absence, to date, of instances of primary cutaneous B-cell lymphoma following mRNA vaccination. Within this context, it is imperative to underscore that the etiological association between PCSM-TCLPD and COVID-19 vaccination should not discourage vaccination efforts. Instead, it underscores the necessity for continuous surveillance, in-depth investigation, and comprehensive follow-up studies to delineate the specific attributes and underlying mechanisms of such cutaneous manifestations post vaccination. Full article
(This article belongs to the Special Issue Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: 2nd Edition)
►▼ Show Figures

Figure 1

15 pages, 3292 KiB  
Article
Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis
by George G. Mitroi, Elena Leocadia Pleșea, George F. Mitroi, Mihaela Roxana Mitroi, Carmen Daniela Neagoe and Simona Laura Ianoși
Life 2024, 14(3), 352; https://doi.org/10.3390/life14030352 - 07 Mar 2024
Viewed by 846
Abstract
Atopic dermatitis (AD) is a persistent inflammatory skin condition that impacts individuals of various age groups, including both children and adults. Its pathophysiology involves allergens penetrating a disrupted epidermal barrier, triggering the dermal cells to produce pro-inflammatory cytokines and eliciting a T-cell-mediated immune [...] Read more.
Atopic dermatitis (AD) is a persistent inflammatory skin condition that impacts individuals of various age groups, including both children and adults. Its pathophysiology involves allergens penetrating a disrupted epidermal barrier, triggering the dermal cells to produce pro-inflammatory cytokines and eliciting a T-cell-mediated immune response. Notably, interleukins (ILs), particularly interleukin 4 (IL-4) and interleukin 13 (IL-13), play a key role in AD pathogenesis. Therapies directed at inflammatory mechanisms, including Dupilumab, have demonstrated notable effectiveness in enhancing skin lesions, alleviating subjective symptoms, and improving the overall quality of life for individuals with AD. Despite therapeutic advances, assessing AD severity remains challenging. The commonly used tools, such as the SCORAD and DLQI scores, rely on subjective patient responses. Paraclinically, the search for universal biomarkers continues, with efforts to identify reliable indicators reflecting disease severity and treatment response. Various biomarkers, including Th2-related chemokines and cytokines, have been explored, but none have gained universal recognition for routine clinical use. This study aims to investigate the dynamics of the plasma levels of IL-4 and IL-13 during Dupilumab treatment and establish correlations between these ILs and disease severity, as measured using the SCORAD and DLQI scores. The ultimate endpoint is to determine whether IL-4 and IL-13 can serve as reliable biomarkers, assessing their correlation with patient-reported feelings and disease activity and potentially influencing their inclusion or exclusion as diagnostic elements in routine clinical practice. Full article
(This article belongs to the Special Issue Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: 2nd Edition)
►▼ Show Figures

Figure 1

12 pages, 1523 KiB  
Article
Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain
by Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Marta Cebolla-Verdugo, Alvaro Prados-Carmona, Carlos Hernández-Montoya, José Carlos Armario-Hita and Manuel Galán-Gutiérrez
Life 2024, 14(3), 281; https://doi.org/10.3390/life14030281 - 20 Feb 2024
Viewed by 755
Abstract
Introduction: Psoriasis, a chronic inflammatory skin disease, affects 2–10% of the population globally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor of IL17 A and F that has shown efficacy in treating moderate to severe plaque psoriasis. This real-world [...] Read more.
Introduction: Psoriasis, a chronic inflammatory skin disease, affects 2–10% of the population globally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor of IL17 A and F that has shown efficacy in treating moderate to severe plaque psoriasis. This real-world evidence (RWE) study aims to assess BMK’s efficiency and safety in naïve and refractory patients. Material and methods: A retrospective analysis of a multicenter observational study included 22 patients treated with BMK from April 2023 to February 2023 in five Andalusian hospitals. Ethical approval was obtained, and patients provided informed consent. Assessment criteria encompassed Psoriasis Area and Severity Index (PASI), body surface area (BSA), VAS pruritus, Dermatology Life Quality Index (DLQI), and minimum disease activity (MDA) at 0, 4, 12, and 24 weeks. Results: Patients, predominantly with plaque psoriasis, exhibited significant improvements in PASI (baseline 15.7 to 0.4 at week 16), BSA (baseline 20.7 to 0.43 at week 16), DLQI (baseline 17.93 to 0.43 at week 16), and pruritus (baseline 7.12 to 0.4 at week 16). At week 16, 95.4% achieved MDA. No safety concerns or treatment discontinuations were reported. Discussion: This RWE study aligns with pivotal clinical trials, confirming BMK’s efficacy and safety. Notably, BMK demonstrated rapid and sustained psoriasis clearance, even in challenging areas. The study’s limitations include a small sample size, suggesting the need for further exploration of patient-reported outcomes. Conclusion: Bimekizumab exhibited optimal efficacy and safety profiles in treating moderate to severe plaque psoriasis in a real-world setting. Rapid response, sustained clearance, and favorable safety outcomes contribute to improved patient experiences. Future research could delve into patient-reported outcomes and expand sample sizes to enhance the understanding of BMK’s real-world effectiveness. Full article
(This article belongs to the Special Issue Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop